Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
[Effect of ticlopidine on peripheral obliterating arteriopathy].
The efficacy of and tolerance to ticlopidine , a platelet inhibitor , in preventing progression of obliterative arterial disease was compared with that of a placebo in a double-blind and r and omized trial in 43 patients ( 22 on placebo , 21 on ticlopidine ) over a period of one year . The course of the disease in both groups was assessed by serial angiography of the lower limbs , both at the beginning and at the end of the study . There was a significantly reduced progression in the ticlopidine group ( P less than 0.01 ) . The results support the hypothesis that platelets are of great importance in the progression of arteriosclerosis and that inhibition of platelet function is an effective principle of prevention . Ticlopidine in this respect is an alternative to the use of acetylsalicylic acid
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .